Background: Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies. Ongoing clinical trials are studying its activity in other malignancies, such as non-small-cell lung cancer (NSCLC). However, no biological marker is known to define either the sensitivity or resistance to the drug. Case presentation: Here we report a case of a patient with two synchronous tumors, HCC and NSCLC, with metastases in the contralateral lung and bone. The patient was treated with gemcitabine as first line, with a resulting progressive disease after two months, and then with sorafenib at standard dosage in the second line setting. After 6 months of treatment CT scan showed a partial response in the primary lesion of the lung, complete response of the metastasis in the contralateral lung, and stability of HCC. The patient had progression in the lung, liver and bone after 13 months of therapy. A molecular characterization of NSCLC and HCC lesions was performed, revealing a BRAF exon 11 mutation (G469V) only in NSCLC. We hypothesize that the response observed in NSCLC lesions could be due to the presence of BRAF mutation, and that this alteration could be responsible in determining sorafenib sensitivity. Conclusions: Results observed in this case encourage further research on the activity of sorafenib in both HCC and NSCLC, based on the presence of BRAF mutation. This could lead to a selection of HCC patients to be treated with this drug, and could help identify a novel treatment strategy for BRAF-mutated NSCLC patients.
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma : A case report / A. Casadei Gardini, E. Chiadini, L. Faloppi, G. Marisi, A. Delmonte, M. Scartozzi, C. Loretelli, A. Lucchesi, D. Oboldi, A. Dubini, G.L. Frassineti, P. Ulivi. - In: BMC CANCER. - ISSN 1471-2407. - 16:1(2016 Jul 07).
|Titolo:||Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma : A case report|
|Parole Chiave:||BRAF; case report; HCC; NSCLC; Sorafenib; Aged; carcinoma, hepatocellular; carcinoma, non-small-cell lung; humans; liver neoplasms; lung neoplasms; male; mutation; neoplasms, multiple primary; niacinamide; phenylurea compounds; proto-oncogene proteins B-raf; treatment outcome; oncology; genetics; cancer research|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Settore BIO/13 - Biologia Applicata
Settore MED/04 - Patologia Generale
|Data di pubblicazione:||7-lug-2016|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/s12885-016-2463-2|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma_ a case report.pdf||Publisher's version/PDF||Open Access Visualizza/Apri|